Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
E7016
i
Other names:
E7016, GPI-21016, GPI -21016
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Eisai
Drug class:
PARP inhibitor
Related drugs:
‹
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
IMP4297 (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
HWH340 (0)
MK-4837 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
olaparib (342)
talazoparib (81)
niraparib (80)
rucaparib (71)
ABT-888 (35)
pamiparib (18)
fluzoparib (12)
JPI-547 (7)
IMP4297 (6)
NOV 1401 (3)
SC10914 (2)
ABT-767 (1)
SBP-101 (1)
AMXI-5001 (0)
AZD2461 (0)
HWH340 (0)
MK-4837 (0)
TSL1502 (0)
[²¹¹At]PTT (0)
kt-3283 (0)
SMOCL-9112 (0)
2X-121 (0)
›
Associations
News
Trials
Filter by
Latest
3ms
Study of Poly (ADP-Ribose) Polymerase (PARP) Inhibitor E7016 in Combination With Temozolomide in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=12, Terminated, Eisai Inc. | Completed --> Terminated; Strategic decision, which is unrelated to safety
3 months ago
Trial termination
|
temozolomide • E7016
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login